New radiation drug trial targets advanced liver cancer
NCT ID NCT06852820
Summary
This study is testing a targeted radiation drug for people with advanced liver cancer that has spread. The drug, called 177Lu-PSMA-617, is designed to find and deliver radiation directly to cancer cells that show a specific marker (PSMA) on a special scan. The main goals are to see if enough patients have the right marker for this approach and to check the treatment's safety and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Seidman Cancer Center
Cleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.